jofinЖурнал инфектологииJournal Infectology2072-6732IPO “АIDSSPbR"10.22625/2072-6732-2022-14-2-47-54jofin-1352Research ArticleОбзорReviewПерсонифицированная терапия бактериофагами заболеваний органов пищеваренияPersonalized therapy with bacteriophages of digestive diseasesГончарН. В.GoncharN. V.

Гончар Наталья Васильевна – и.о. руководителя научно-исследовательского отдела кишечных инфекций, ведущий научный сотрудник; профессор кафедры педиатрии и неонатологии; д.м.н.; тел.: +7-921- 369-32-97

Санкт-Петербург

Saint-Petersburg

nvgonchar@yandex.ruЕрмоленкоК. Д.ErmolenkoK. D.

Ермоленко Константин Дмитриевич – научный сотрудник научно-исследовательского отдела кишечных инфекций; тел.: +7-952-371-28-80

Санкт-Петербург

Saint-Petersburg

ermolenko.kd@yandex.ruСкрипченкоН. В.SkripchenkoN. V.

Скрипченко Наталья Викторовна – заместитель директора по научной работе; заведующая кафедрой инфекционных болезней у детей ФПК и ПП; д.м.н., профессор, заслуженный деятель науки РФ; тел.: 8(812) 234-38-22

Санкт-Петербург

Saint-Petersburg

snv@niidi.ruДетский научно-клинический центр инфекционных болезней; Северо-Западный государственный медицинский университет им. И.И. МечниковаРоссияPediatric Research and Clinical Center for Infectious Diseases; North-Western State Medical University named after I.I. MechnikovRussian FederationДетский научно-клинический центр инфекционных болезнейРоссияPediatric Research and Clinical Center for Infectious DiseasesRussian FederationДетский научно-клинический центр инфекционных болезней; Санкт-Петербургский государственный педиатрический медицинский университетРоссияPediatric Research and Clinical Center for Infectious Diseases; Saint-Petersburg State Pediatric Medical UniversityRussian Federation2022130720221424754Copyright © Гончар Н.В., Ермоленко К.Д., Скрипченко Н.В., 20222022Гончар Н.В., Ермоленко К.Д., Скрипченко Н.В.Gonchar N.V., Ermolenko K.D., Skripchenko N.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.niidi.ru/jofin/article/view/1352

Современные представления о тесной взаимосвязи здоровья человека и микробиоты кишечника, а также последние достижения молекулярной биологии, свидетельствующие о значимой роли вирома кишечника, способствуют проведению исследований терапевтической пользы бактериофагов.

Цель данного обзора – рассмотреть перспективы применения бактериофагов для коррекции микробиоты кишечника и терапии заболеваний органов пищеварения.

В обзоре описаны основы биологии фагов, особенности бактериофагового вирома кишечника при гастроэнтерологической патологии; освещены вопросы современных методов терапии и профилактики на основе фагов, рассмотрены проблемы фаговой терапии и пути их преодоления. Показано, что использование фагов может стать ключевым персонализированным подходом к лечению и профилактике инфекционных и неинфекционных гастроэнтерологических заболеваний.

Current insights into the close relationship between human health and the gut microbiota, as well as recent advances in molecular biology suggesting a significant role for gut viromas, have encouraged research into the therapeutic usefulness of bacteriophages.

The purpose of this review is to consider the prospects for the use of bacteriophages for the correction of the gut microbiota and therapy of digestive system diseases.

The review describes the basics of phage biology, peculiarities of bacteriophage virome of the intestine in gastroenterological pathology; it highlights modern methods of phage-based therapy and prevention, considers problems of phage therapy and ways to overcome them. It is shown that the use of phages can become a key personalized approach to the treatment and prevention of infectious and non-infectious gastroenterological diseases.

бактериофагимикробиота кишечникабактериофаговый виром кишечниказаболевания органов пищеварениятерапияbacteriophagesgut microbiotabacteriophage gut virusdigestive diseasestherapyReferencesYoung V.B. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017; 356: j831.Young V.B. The role of the microbiome in human health and disease: an introduction for clinicians. BMJ. 2017; 356: j831.Феклисова, Л.В. Дисбиотические нарушения слизистых оболочек ротоглотки у детей c рекуррентными респираторными заболеваниями в различные периоды / Л.В. Феклисова, Е.А. Медведева // Инфекционные болезни. 2016. – Т. 14, № 2. – С. 24–28.Feklisova L.V., Medvedeva E.A. Disbioticheskie narusheniya slizisty`x obolochek rotoglotki u detej c rekurrentny`mi respiratorny`mi zabolevaniyami v razlichny`e periody`. Infekcionny`e bolezni. 2016; 14(2): 24–28 (in Russian)Shkoporov A.N., Hill C. Bacteriophages of the human gut: the “known unknown” of the microbiome. Cell Host Microbe. 2019; 25 (2): 195–209.Shkoporov A.N., Hill C. Bacteriophages of the human gut: the “known unknown” of the microbiome. Cell Host Microbe. 2019; 25 (2): 195–209.Summers W.C. Bacteriophage therapy. Annu. Rev. Microbiol. 2001; 55: 437–451.Summers W.C. Bacteriophage therapy. Annu. Rev. Microbiol. 2001; 55: 437–451.Aminov R. History of antimicrobial drug discovery: major classes and health impact. Biochem. Pharmacol. 2017; 133: 4–19.Aminov R. History of antimicrobial drug discovery: major classes and health impact. Biochem. Pharmacol. 2017; 133: 4–19.Николаева, С.В. Что нужно знать об антибактериальной терапии респираторных инфекций у детей. Правильный старт – успешный финиш / С.В. Николаева [и др.] // Инфекционные болезни. 2020. – Т. 18, № 4. – С. 195–200.Nikolaeva S.V., Usenko D.V., Shabalina S.V., et al. Chto nuzhno znat` ob antibakterial`noj terapii respiratorny`x infekcij u detej. Pravil`ny`j start – uspeshny`j finish. Infekcionny`e bolezni. 2020; 18(4): 195–200 (in Russian)Becattini S., Taur Y., Pamer E.G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 2016; 22 (6): 458–478.Becattini S., Taur Y., Pamer E.G. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol. Med. 2016; 22 (6): 458–478.Mushegian A.R. Are there 10 31 virus particles on earth, or more, or fewer? J. Bacteriol. 2020; 202 (9): e00052-20.Mushegian A.R. Are there 10 31 virus particles on earth, or more, or fewer? J. Bacteriol. 2020; 202 (9): e00052-20.Duan Y., Young R., Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat. Rev. Gastroenterol. Hepatol. 2021. https://doi.org/10.1038/s41575-021-00536-z.Duan Y., Young R., Schnabl B. Bacteriophages and their potential for treatment of gastrointestinal diseases. Nat. Rev. Gastroenterol. Hepatol. 2021. https://doi.org/10.1038/s41575-021-00536-z.Pratama A.A., van Elsas J.D. The “neglected” soil virome-potential role and impact. Trends Microbiol. 2018; 26 (8): 649–662.Pratama A.A., van Elsas J.D. The “neglected” soil virome-potential role and impact. Trends Microbiol. 2018; 26 (8): 649–662.Dion M.B., Oechslin F., Moineau S. Phage diversity, genomics and phylogeny. Nat. Rev. Microbiol. 2020; 18 (3): 125–138.Dion M.B., Oechslin F., Moineau S. Phage diversity, genomics and phylogeny. Nat. Rev. Microbiol. 2020; 18 (3): 125–138.Hatfull G.F. Bacteriophage genomics. Curr. Opin. Microbiol. 2008; 11 (5): 447–453.Hatfull G.F. Bacteriophage genomics. Curr. Opin. Microbiol. 2008; 11 (5): 447–453.Al-Shayeb B., Sachdeva R., Chen L.-X., et al. Clades of huge phages from across earth’s ecosystems. Nature. 2020; 578 (7795): 425–431.Al-Shayeb B., Sachdeva R., Chen L.-X., et al. Clades of huge phages from across earth’s ecosystems. Nature. 2020; 578 (7795): 425–431.Gregory A.C., Zablocki O., Zayed A.A., et al. The gut virome database reveals age-dependent patterns of virome diversity in the human gut. Cell Host Microbe. 2020; 28 (5): 724–740.Gregory A.C., Zablocki O., Zayed A.A., et al. The gut virome database reveals age-dependent patterns of virome diversity in the human gut. Cell Host Microbe. 2020; 28 (5): 724–740.Ofir G., Sorek R. Contemporary phage biology: from classic models to new insights. Cell. 2018; 172 (6): 1260–1270.Ofir G., Sorek R. Contemporary phage biology: from classic models to new insights. Cell. 2018; 172 (6): 1260–1270.Silva J.B. Storms Z., Sauvageau D. Host receptors for bacteriophage adsorption. FEMS Microbiol. Lett. 2016; 363 (4): fnw002.Silva J.B. Storms Z., Sauvageau D. Host receptors for bacteriophage adsorption. FEMS Microbiol. Lett. 2016; 363 (4): fnw002.Young R. Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 1992; 56 (3): 430–481.Young R. Bacteriophage lysis: mechanism and regulation. Microbiol. Rev. 1992; 56 (3): 430–481.Dou C., Xiong J., Gu Y., et al. Structural and functional insights into the regulation of the lysis-lysogeny decision in viral communities. Nat. Microbiol. 2018; 3 (11): 1285–1294.Dou C., Xiong J., Gu Y., et al. Structural and functional insights into the regulation of the lysis-lysogeny decision in viral communities. Nat. Microbiol. 2018; 3 (11): 1285–1294.Howard-Varona C., Hargreaves K.R., Abedon S.T., Sullivan M.B. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISMEJ. 2017; 11 (7): 1511–1520.Howard-Varona C., Hargreaves K.R., Abedon S.T., Sullivan M.B. Lysogeny in nature: mechanisms, impact and ecology of temperate phages. ISMEJ. 2017; 11 (7): 1511–1520.Bondy-Denomy J., Qian J., Westra E.R., et al. Prophages mediate defense against phage infection through diverse mechanisms. ISMEJ. 2016; 10: 2854–2866.Bondy-Denomy J., Qian J., Westra E.R., et al. Prophages mediate defense against phage infection through diverse mechanisms. ISMEJ. 2016; 10: 2854–2866.Fortier L.C., Sekulovic O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence. 2013; 4 (5): 354–365.Fortier L.C., Sekulovic O. Importance of prophages to evolution and virulence of bacterial pathogens. Virulence. 2013; 4 (5): 354–365.Alexeeva S., Guerra Martinez J.A., Spus M., Smid E.J. Spontaneously induced prophages are abundant in a naturally evolved bacterial starter culture and deliver competitive advantage to the host. BMC Microbiol. 2018; 18 (1): 120.Alexeeva S., Guerra Martinez J.A., Spus M., Smid E.J. Spontaneously induced prophages are abundant in a naturally evolved bacterial starter culture and deliver competitive advantage to the host. BMC Microbiol. 2018; 18 (1): 120.Nanda A.M., Thormann, K., Frunzke J. Impact of spontaneous prophage induction on the fitness of bacterial populations and host-microbe interactions. J. Bacteriol. 2015; 197 (3): 410–419.Nanda A.M., Thormann, K., Frunzke J. Impact of spontaneous prophage induction on the fitness of bacterial populations and host-microbe interactions. J. Bacteriol. 2015; 197 (3): 410–419.Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 2010; 8: 317–327.Labrie S.J., Samson J.E., Moineau S. Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 2010; 8: 317–327.Dufour N., Clermont O., La Combe B., et al. Bacteriophage LM33_P 1, a fast-acting weapon against the pandemic ST 131-025b:H4 Escherichia coli clonal complex. J. Antimicrob. Chemother. 2016; 71 (11): 3072–3080.Dufour N., Clermont O., La Combe B., et al. Bacteriophage LM33_P 1, a fast-acting weapon against the pandemic ST 131-025b:H4 Escherichia coli clonal complex. J. Antimicrob. Chemother. 2016; 71 (11): 3072–3080.Liang G., Zhao C., Zhang H., et al. The stepwise assembly of the neonatal virome is modulated by breastfeeding. Nature. 2020; 581 (7809): 470–474.Liang G., Zhao C., Zhang H., et al. The stepwise assembly of the neonatal virome is modulated by breastfeeding. Nature. 2020; 581 (7809): 470–474.Lim E.S., Wang D., Holtz L.R. The bacterial microbiome and virome milestones of infant development. Trends Microbiol. 2016; 24 (10): 801–810.Lim E.S., Wang D., Holtz L.R. The bacterial microbiome and virome milestones of infant development. Trends Microbiol. 2016; 24 (10): 801–810.Shapiro J.W., Putonti C. Gene co-occurrence networks reflect bacteriophage ecology and evolution. mBio. 2018; 9 (2): eO1870–1917.Shapiro J.W., Putonti C. Gene co-occurrence networks reflect bacteriophage ecology and evolution. mBio. 2018; 9 (2): eO1870–1917.Santiago-Rodriguez T.M., Hollister E.B. Human virome and disease: high-throughput sequencing for virus discovery, identification of phage-bacteria dysbiosis and development of therapeutic approaches with emphasis on the human gut. Viruses. 2019; 11: 656.Santiago-Rodriguez T.M., Hollister E.B. Human virome and disease: high-throughput sequencing for virus discovery, identification of phage-bacteria dysbiosis and development of therapeutic approaches with emphasis on the human gut. Viruses. 2019; 11: 656.Pourcel C., Midoux C., Vergnaud G., Latino L. A carrier state is established in Pseudomonas aeruginosa by phage LeviOrOl, a newly isolated ssRNA levivirus. J. Gen. Virol. 2017; 98 (8): 2181–2189.Pourcel C., Midoux C., Vergnaud G., Latino L. A carrier state is established in Pseudomonas aeruginosa by phage LeviOrOl, a newly isolated ssRNA levivirus. J. Gen. Virol. 2017; 98 (8): 2181–2189.Tripathi A., Debelius J., Brenner D.A., et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 2018; 15 (7): 397–411.Tripathi A., Debelius J., Brenner D.A., et al. The gut-liver axis and the intersection with the microbiome. Nat. Rev. Gastroenterol. Hepatol. 2018; 15 (7): 397–411.Алексанина, Н.В. Фагорезистентность условнопатогенных бактерий кишечной микробиоты у детей с нарушениями микробиоценоза / Н.В. Алексанина, Т.И. Твердохлебова // Журнал инфектологии. – 2021. – Т. 13, № 2. – С. 102–107.Aleksanina N.V., Tverdoxlebova T.I. Fagorezistentnost` uslovno-patogenny`x bakterij kishechnoj mikrobioty` u detej s narusheniyami mikrobiocenoza. Zhurnal infektologii. 2021; 13 (2): 102 – 107 (in Russian)Clooney A.G., Sutton T.D.S., Shkoporov A.N., et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease. Cell Host Microbe. 2019; 26 (6): 764–778.Clooney A.G., Sutton T.D.S., Shkoporov A.N., et al. Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease. Cell Host Microbe. 2019; 26 (6): 764–778.Coughlan S., Das A., O’Herlihy E., et al. The gut virome in irritable bowel syndrome differs from that of controls. Gut Microbes. 2021; 13 (1): 1–15.Coughlan S., Das A., O’Herlihy E., et al. The gut virome in irritable bowel syndrome differs from that of controls. Gut Microbes. 2021; 13 (1): 1–15.Lepage P., Colombet J., Marteau P., et al. Dysbiosis in inflammatory bowel disease: a role for bacteriophages? Gut. 2008; 57 (3): 424–425.Lepage P., Colombet J., Marteau P., et al. Dysbiosis in inflammatory bowel disease: a role for bacteriophages? Gut. 2008; 57 (3): 424–425.Zuo T., Lu X.-J., Zhang Y., et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019; 68 (7): 1169–1179.Zuo T., Lu X.-J., Zhang Y., et al. Gut mucosal virome alterations in ulcerative colitis. Gut. 2019; 68 (7): 1169–1179.Norman J.M., Handley S.A., Baldridg M.T., et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015; 160 (3): 447–460.Norman J.M., Handley S.A., Baldridg M.T., et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell. 2015; 160 (3): 447–460.Nakatsu G., Zhou H., Wu K.K.W., et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018; 155 (2): 529–541.e5.Nakatsu G., Zhou H., Wu K.K.W., et al. Alterations in enteric virome are associated with colorectal cancer and survival outcomes. Gastroenterology. 2018; 155 (2): 529–541.e5.Jiang L., Lang S., Duan Y., et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology. 2020; 72 (6): 2182–2196.Jiang L., Lang S., Duan Y., et al. Intestinal virome in patients with alcoholic hepatitis. Hepatology. 2020; 72 (6): 2182–2196.Lang S., Demir M., Wisplinghoff H., et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020; 159 (5): 1839–1852.Lang S., Demir M., Wisplinghoff H., et al. Intestinal virome signature associated with severity of nonalcoholic fatty liver disease. Gastroenterology. 2020; 159 (5): 1839–1852.Саперкин, Н.В. Эффективность использования бактериофагов для лечения и профилактики инфекции: систематический обзор / Н.В. Саперкин [и др.] // Журнал инфектологии. – 2019. – Т. 11, № 4. – С. 19–30.Saperkin N.V., Kovalishena O.V., Kvashnina D.V., et al. E`ffektivnost` ispol`zovaniya bakteriofagov dlya lecheniya i profilaktiki infekcii: sistematicheskij obzor. Zhurnal infektologii. 2019; 11 (4): 19 – 30 (in Russian)Асланов, Б.И. Бактериофаги как эффективные противоэпидемические средства для купирования вспышек внутрибольничных инфекций / Б.И. Асланов, А.В. Любимова, Л.П. Зуева // Журнал инфектологии. – 2019. Т. 11, № 1. – С. 65–70.Aslanov B.I., Lyubimova A.V., Zueva L.P. Bakteriofagi kak e`ffektivny`e protivoe`pidemicheskie sredstva dlya kupirovaniya vspy`shek vnutribol`nichny`x infekcij. Zhurnal infektologii. 2019; 11 (1): 65 – 70. (In Russian)Sarker S.A., Berger B., Deng Y., et al. Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ. Microbiol. 2017; 19 (1): 237–250.Sarker S.A., Berger B., Deng Y., et al. Oral application of Escherichia coli bacteriophage: safety tests in healthy and diarrheal children from Bangladesh. Environ. Microbiol. 2017; 19 (1): 237–250.Sarker S.A., Sultana S., Reuteler G., et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine. 2016; 4: 124–137.Sarker S.A., Sultana S., Reuteler G., et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: a randomized trial in children from Bangladesh. EBioMedicine. 2016; 4: 124–137.Yen M., Cairns L.S., Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat. Commun. 2017; 8: 14187.Yen M., Cairns L.S., Camilli A. A cocktail of three virulent bacteriophages prevents Vibrio cholerae infection in animal models. Nat. Commun. 2017; 8: 14187.Gindin M., Febvre H.P, Rao S., et al. Bacteriophage for Gastrointestinal Health (PHAGE) study: evaluating the safety and tolerability of supplemental bacteriophage consumption. J. Am. Coll. Nutr. 2019; 38 (1): 68–75.Gindin M., Febvre H.P, Rao S., et al. Bacteriophage for Gastrointestinal Health (PHAGE) study: evaluating the safety and tolerability of supplemental bacteriophage consumption. J. Am. Coll. Nutr. 2019; 38 (1): 68–75.Grubb D.S., Wrigley S.D., Freedman K., et al. PHAGE-2 study: supplemental bacteriophages extend Bifidobacterium animalis subsp. lactis BL04 benefits on gut health and microbiota in healthy adults. Nutrients. 2020; 12 (8): 2474.Grubb D.S., Wrigley S.D., Freedman K., et al. PHAGE-2 study: supplemental bacteriophages extend Bifidobacterium animalis subsp. lactis BL04 benefits on gut health and microbiota in healthy adults. Nutrients. 2020; 12 (8): 2474.Galtier M., De Sordi L., Sivignon A., et al. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J. Crohn’s Colitis. 2017; 11 (7): 840–847.Galtier M., De Sordi L., Sivignon A., et al. Bacteriophages targeting adherent invasive Escherichia coli strains as a promising new treatment for Crohn’s disease. J. Crohn’s Colitis. 2017; 11 (7): 840–847.Duan Y., Llorente C., Lang S., et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019; 575 (7783): 505–511.Duan Y., Llorente C., Lang S., et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature. 2019; 575 (7783): 505–511.Wirbel J., Pyl P.T., Kartal E., et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 2019; 25 (4): 679–689.Wirbel J., Pyl P.T., Kartal E., et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat. Med. 2019; 25 (4): 679–689.Yacoby I., Bar H., Benhar I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob. Agents Chemother. 2007; 51 (6): 2156–2163.Yacoby I., Bar H., Benhar I. Targeted drug-carrying bacteriophages as antibacterial nanomedicines. Antimicrob. Agents Chemother. 2007; 51 (6): 2156–2163.Zheng D.W., Dong X., Pan P., et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 2019; 3 (9): 717–728.Zheng D.W., Dong X., Pan P., et al. Phage-guided modulation of the gut microbiota of mouse models of colorectal cancer augments their responses to chemotherapy. Nat. Biomed. Eng. 2019; 3 (9): 717–728.Sweere J.M., Van Belleghem J.D., Ishak H., et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science. 2019; 363 (6434): eaat9691.Sweere J.M., Van Belleghem J.D., Ishak H., et al. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Science. 2019; 363 (6434): eaat9691.Gogokhia L., Buhrke K., Bell R., et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe. 2019; 25 (2): 285–299.e8.Gogokhia L., Buhrke K., Bell R., et al. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell Host Microbe. 2019; 25 (2): 285–299.e8.Zhang L., Hou X., Sun L., et al. Staphylococcus aureus bacteriophage suppresses LPS-induced inflammation in MAC-T bovine mammary epithelial cells. Front. Microbiol. 2018; 9: 1614.Zhang L., Hou X., Sun L., et al. Staphylococcus aureus bacteriophage suppresses LPS-induced inflammation in MAC-T bovine mammary epithelial cells. Front. Microbiol. 2018; 9: 1614.Merabishvili M., Pirnay J.P., De Vos D. In Bacteriophage therapy: From Lab to Clinical Practice (eds Azeredo J., Sillankorva S.). Springer, 2018: 99–110.Merabishvili M., Pirnay J.P., De Vos D. In Bacteriophage therapy: From Lab to Clinical Practice (eds Azeredo J., Sillankorva S.). Springer, 2018: 99–110.Friman V.P., Soanes-Brown D., Sierocinski P., et al. Preadapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evolut. Biol. 2016; 29 (1): 188–198.Friman V.P., Soanes-Brown D., Sierocinski P., et al. Preadapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evolut. Biol. 2016; 29 (1): 188–198.Dunne M., Rupf B., Tala M., et al. Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins. Cell Rep. 2019; 29 (5): 1336–1350.Dunne M., Rupf B., Tala M., et al. Reprogramming bacteriophage host range through structure-guided design of chimeric receptor binding proteins. Cell Rep. 2019; 29 (5): 1336–1350.Capparelli R., Parlato M., Borriello G., et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 2007; 51 (8): 2765–2773.Capparelli R., Parlato M., Borriello G., et al. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob. Agents Chemother. 2007; 51 (8): 2765–2773.Fauconnier A. In Bacteriophage therapy: From Lab to Clinical Practice (eds Azeredo, J. & Sillankorva, S.). Springer, 2018: 253–268.Fauconnier A. In Bacteriophage therapy: From Lab to Clinical Practice (eds Azeredo, J. & Sillankorva, S.). Springer, 2018: 253–268.

The authors declare that there are no conflicts of interest present.